AbbVie's Secret Weapon for Crohn's Patients Everyone Else Gave Up On

AFFIRM tested an all-subcutaneous regimen, meaning patients could potentially skip the IV chair entirely. For patients juggling jobs, childcare, and the general chaos of life with a chronic illness, that's a massive quality-of-life upgrade. It also removes a logistical barrier that can delay treatment initiation, particularly in rural areas or overburdened health systems.

If AbbVie secures an expanded label for SC induction, Skyrizi becomes a fully at-home treatment from day one. That's a competitive advantage money can't easily buy.

The $17.5 Billion Franchise Gets Bigger

Let's talk business, because this trial doesn't exist in a vacuum. Skyrizi is the cornerstone of AbbVie's post-Humira strategy, and it's already performing like a franchise player.

In 2024, Skyrizi generated $11.72 billion in revenue, up 51% from the year prior. Projections for 2025 land around $17.5 billion. For perspective, that single drug is on pace to generate more revenue than most mid-cap biotech companies are worth.

Meanwhile, Humira (once the world's best-selling drug) declined approximately 57.6% to $8.99 billion in 2024 as biosimilars ate into its market. Skyrizi and its sibling Rinvoq have more than picked up the slack, combining for roughly $25.9 billion in projected 2025 sales. AbbVie isn't just surviving the Humira patent cliff; it's thriving on the other side.

The AFFIRM data could extend that growth curve even further. An SC-only label would make Skyrizi easier to prescribe, easier to start, and harder for competitors to displace. AbbVie reportedly captures about 75% of frontline IBD patient starts in the IL-23 inhibitor class. That kind of market dominance, combined with a convenience upgrade, is how you build a moat.

The Competitive Chess Match

AbbVie isn't playing solitaire. Johnson & Johnson's Tremfya (guselkumab), another IL-23 inhibitor, is projected to hit $5.2 billion in 2025 sales and is aggressively pursuing its own Crohn's disease indications. The convenience of a fully subcutaneous regimen could help Skyrizi maintain its lead, since doctors and patients tend to gravitate toward the path of least resistance.

The broader treatment landscape is also shifting in Skyrizi's favor. That means more patients could be eligible for IL-23 inhibitors earlier in their disease course, expanding the addressable market for drugs like Skyrizi.

And the long-term data backing IL-23 inhibitors is encouraging. These drugs don't just work; they keep working.

The Safety Story Was Quietly Impressive

Phase 3 trials aren't just about efficacy. The safety data from AFFIRM were reassuring, with no new risks popping up beyond what's already known. Serious adverse events occurred in just 0.5% of the Skyrizi group, compared to 3.1% on placebo. You read that right: patients on the active drug had fewer serious side effects than those on placebo. The most common complaints were upper respiratory infections, abdominal pain, and joint aches.

For a chronic disease that requires years (often decades) of treatment, a clean safety profile isn't a footnote. It's the foundation that lets doctors prescribe with confidence.

What Happens Next

AbbVie will likely pursue a supplemental filing with the FDA to add subcutaneous induction to Skyrizi's Crohn's disease label. If approved, it would remove the last major inconvenience hurdle separating Skyrizi from a truly patient-friendly treatment experience.

For the 65% of Crohn's patients in AFFIRM who had already run through their other options, these results offer something clinical data rarely captures: hope that the next treatment might actually be the one that sticks. And for AbbVie shareholders watching the Humira transition, AFFIRM is another data point confirming that the succession plan is working better than almost anyone expected.